Other

Case Western Reserve University

Mirx Pharmaceuticals, LLC

Invenio Therapeutics Inc.

Mukesh Agarwal

Mahesh Kumar Gundluru

David Wald

Goutam Karan

Zhiqing Xia

Zhiqiang Xia

Arvind Kumar Sharma

Apparatuses and methods for preparation of breads are described. The apparatuses include a press unit that can receive a dough ball and flatten the dough ball. The press unit includes a top plate and a bottom plate, each of which is in an inclined arrangement. The top plate swivels towards and away from the bottom plate. A dough ball is flattened between the top plate and the bottom plate. The bottom plate is heated, thereby heating a first face of the flattened dough in contact with the bottom plate. A flipper connected to at least one of the top plate and the bottom plate guides the flattened dough to a heated cooking surface. The guiding enables a second face of the flattened dough to come in contact with the cooking surface, thereby heating the flattened dough and forming the bread.

Automated preparation of breads

The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders

The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.

HDMX inhibitors and their use for cancer treatment

The present invention relates to use of novel securinine and norsecurine analogs to bind and/or inhibit myeloperoxidase activity.

Small molecule securinine and norsecurinine analogs and their use in inhibiting myeloperoxidase

The present application relates to securinine or norsecurinine analogs that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.

Growing community of inventors

Solon, OH, United States of America

Mukesh Agarwal